FDA oversight, cGMP compliance, adverse event reporting requirements, and regular inspections create accountability mechanisms that do not exist for most 503A pharmacies
Active inflammation, ongoing steroid therapy for flare management, or recent hospitalizations for bowel obstruction are contraindications that warrant postponing GLP-1 treatment
Fortunately, GLP-1RAs seem to have the potential to become a multi-target medicine
Matza LS, Boye KS, Currie BM, et al
Sanyal AJ, Bedossa P, Fraessdorf M, Neff GW, Lawitz E, Bugianesi E, Anstee QM, Hussain SA, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Noureddin M, Alkhouri N, Younes R
Traditional treatments like hydroquinone suppress melanin production while youre using them, but they dont address the underlying triggers which is why the pigmentation returns when you stop